welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Cancer Prevention Pharmaceuticals Completes Target Enrollment in Pivotal Phase 3 Clinical Trial Evaluating CPP-1X/sulindac in Patients with Familial Adenomatous Polyposis
Cancer Prevention Pharmaceuticals, Inc. (CPP), a private biotech company developing novel therapeutics to prevent cancer and other diseases, announced today that target enrollment has been achieved for the company’s pivotal Phase 3 clinical trial, CPP FAP-310, evaluating CPP-1X/sulindac in adults with familial adenomatous polyposis (FAP).
expertly curated content related to this topic
-
#jpouchFAP hashtag for the community...
-
Familial adenomatous polyposis monitoring, Whipple procedure gave my husband more timeWhen he was 15, my husband Jesse underwe...
-
Sulindac for Periampullary Polyps in FAP PatientsBACKGROUND : Gastro-duodenal polyps deve...
-
A Prospective Multicenter Phase II Study of Sunitinib in Patients With Advanced Aggressive FibromatosisSeveral studies have reported that imati...
-
Familial Adenomatous Polyposis: Ileo-Anal Pouch versus Ileo-Rectal AnastomosisAIM : In this study we describe the pres...
-
French Digestive Polyposis CohorteFrench cohorte about polyposis digestive...
-
Clinical Practice Guidelines for the Prevention, Early Detection and Management of Colorectal CancerExecutive Summary Colorectal Cancer con...
English
Portuguese
Spanish